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To evaluate the potential benefit of MDL 17043, a new
inotrope-vasodilator agent, in the short- and long-term
management of severe heart failure, its hemodynamic
effects were determined after both intravenous (cumu-
lative average dose 3.7 mg/kg) and oral (average 18.4
mg/kg) administration in 38 patients with severe intract-
able heart failure. After both intravenous and oral ther-
apy, cardiac index increased from a control value of 2.1
± 0.4 to 3.6 ± 0.9 liters/min per nr', p<O.OOI (intra-
venous) and from 2.2 ± 0.5 to 3.4 ± 0.6 liters/min per
m2, p<O.OOl (oral). Pulmonary capillary wedgepressure
decreased from 26 ± 6 to 14 ± 7 mm Hg (p<O.OOI)
and from 26 ± 7 to 18 ± 8 mm Hg (p<O.OOI) after
intravenous and oral routes, respectively. Stroke vol-
ume index and stroke work index increased, and right
atrial and pulmonary arterial pressures and systemic
vascular resistance decreased by similar magnitude after
both intravenous and oral MDL 17043 (all p<O.OOI).
The hemodynamic effects persisted during 4 hours of
observation.
Therapy for chronic congestive heart failure refractory to
conventional treatment is frequently directed at manipulat-
ing left ventricular loading conditions with vasodilator agents
in an attempt to reduce pulmonary and systemic congestion
and to increase cardiac output (1-3). Improved contractile
function with inotropic therapy also enhances cardiac per-
formance. Thus, pharmacologic agents with both vasodi-
lating and positive inotropic properties can be useful in the
management of severe heart failure (4). MDL 17043, a
nonglycoside, noncatecholamine imidazole derivative (1,3
dihydro-4 methyl-5-[(methylthio) benzoyl]-2H-imidazole-2-
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Thirty-seven patients were discharged whilereceiving
MDL 17043 therapy and were followed up for a mean
of 5.6 months (range 0.5 to 13). Thirty-three of the 37
patients had short-term improvement clinically by at
least one New York Heart Association functional class.
Undesirable effects, including nausea (35%), anorexia
(27%), fluid retention (24%) and thrombocytopenia
« 1%), necessitated discontinuation of therapy in 11
patients (30%) who were receiving multiple drug ther-
apy. Six of seven patients who discontinued MDL 17043
on their own (out of the hospital) died within 1 week of
doing so. In 24 patients who continued receiving long-
term therapy, at a mean follow-up period of 6.1 months
(range 1 to 13)there was a 50% mortality rate. Mortality
was 62% for class IV and 18% for class III patients.
Thus, if tolerated, MDL 17043causes clinical improve-
ment without apparently improving survival in patients
with severe refractory congestive heart failure.
one) with phosphodesterase-inhibiting properties (5), has
been shown to have inotropic properties in vitro (6). Recent
investigations (6-8) have demonstrated not only its positive
inotropic property, but also its potential to decrease systemic
vascular resistance when given intravenously. Oral MDL
17043 improves myocardial contractile function in animal
models and its long-term administration in this setting has
been free of toxic effects (6). The purpose of this study was
to compare the short-term hemodynamic effects of intra-
venous and oral MDL 17043 in the same patients with severe
chronic congestive heart failure and to assess the clinical
course and incidence of adverse side effects in patients re-
ceiving long-term therapy.
Methods
Study patients. Thirty-eight patients with chronic
congestive heart failure refractory to conventional therapy
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were studied. The study group included 28 men and 10
women with a mean age of 60 years (range 47 to 76). The
cause of congestive failure was ischemic heart disease in
26 patients, idiopathic dilated cardiomyopathy in 8 patients
and persistent severe left ventricular dysfunction after aortic
or mitral valve replacement in 4 patients. All patients were
receiving digitalis and diuretic drugs, and 29 received treat-
ment with one or more vasodilator agents, including nitrates,
hydralazine, prazosin or captopril, before the study. The
duration of congestive failure averaged 30 months (range 2
to 120). Twenty-six patients were in New York Heart As-
sociation functional class IV and 12 were in class III at the
time of entry into the study.
Hemodynamic measurements. All vasodilators were
discontinued at least 24 hours before the study, but daily
maintenance doses of digitalis and diuretic drugs were con-
tinued. After informed consent was obtained, a no. 7 triple
lumen balloon flotation catheter was placed in the pulmonary
artery to determine right atrial, pulmonary artery and pul-
monary capillary wedge pressures. Cardiac output was de-
termined by the thermodilution technique with the use of
the same catheter (9). Arterial pressure was recorded directly
by cannulation of a radial artery.
Derived hemodynamic variables were calculated as fol-
lows: Cardiac index (CI; liters/min per nr') = CO/BSA,
where CO = cardiac output and BSA = body surface area
in rrr'. Stroke volume index (SVI; ml/rrr') = CIIHR, where
HR is heart rate in beats/min. Stroke work index (SWI;
g-m/rrr') = [(MSP- PCW) x SVI x 0.0136], where MSP
= mean systolic pressure and PCW = mean pulmonary
capillary wedge pressure. Systemic vascular resistance (SVR;
dynes-s-cm") = [(MAP - RAP] x 80], where MAP =
mean arterial pressure and RAP = right atrial pressure.
Pulmonary vascular resistance (PVR; dynes-scm - 5) = [(PAP
- PCWP)/CO] x 80], where PAP = mean pulmonary
artery pressure. Thirty minutes after catheter placement (rest
period), two sets of baseline pressure and cardiac output
values were obtained.
MDL 17043 administration. After the control mea-
surements, MDL 17043 was administered by slow intra-
venous infusion (rate 12.5 mg/min) in incremental doses of
0.5, 1.0 and 1.5 mg/kg body weight at 20 minute intervals.
Hemodynamic variables were measured immediately after
each dose and at approximately 12.5 minutes after a dose.
Subsequent doses of 1.5 mg/kg were administered at 20
minute intervals until there was a plateau in cardiac output
response, heart rate increased by more than 15% or to more
than 120 beats/min, systolic blood pressure decreased by
more than 20% or decreased to less than 85 mm Hg, pul-
monary capillary wedge pressure decreased to less than 10
mm Hg or a cumulative dose of 10 mg/kg was administered.
After the final dose of MDL 17043, hemodynamic mea-
surements were obtained at 12.5 and 30 minutes and 1,2,
3 and 4 hours.
Oral MDL 17043 was administered on the day after
hemodynamic measurements had returned to baseline pre-
treatment levels. The first 31 patients received MDL 17043
liquid suspension, with capsules being given to the final 8
patients. Again, after two baseline hemodynamic measure-
ments, oral drug was administered in 1.0 mg/kg increments
from a starting dose of 2.0 mg/kg. Hemodynamic mea-
surements were made at 12.5 and 30 minutes after each
dose, and subsequent doses were then given until either a
hemodynamic end point was reached (as just described) or
a single maximal dose of 10 mg/kg was given. Hemody-
namic measurements were repeated at 12.5 and 30 minutes
and 1, 2, 3 and 4 hours after the administration of the
maximal dose.
Statistical analysis. Repeated measures analysis of var-
iance was used to assess the hemodynamic effects of the
drug in relation to time after both intravenous and oral
administration. If the analysis of variance was statistically
significant at the 5% level or less for either route, time or
route-time interaction, Tukey's method for multiple com-
parison was used (10). Peak effect was defined as the highest
cardiac output achieved after the maximal dose of MDL
17043 administered. A Cox multivariate regression analysis
was used to assess the relation of baseline and peak effect
hemodynamic variables, cause of congestive heart failure
and functional class at entry to subsequent survival.
Results
Hemodynamic effects. The hemodynamic effects up to
4 hours after both intravenous and oral MDL 17043 in all
38 patients are summarized in Tables 1 and 2. The control
hemodynamic measurements before intravenous and oral
drug therapy were similar. The mean cumulative dose of
MDL 17043 administered was 3.7 mg/kg (range 0.5 to 10)
intravenously and 18.4 mg/kg (range 2 to 31.5 mg) orally.
The mean time to peak drug effect after the maximal dose
given was 22 minutes after intravenous and 36 minutes after
oral administration. There was no significant change in heart
rate after oral or intravenous administration of the drug. A
significant but modest decrease in mean arterial pressure
was noted after both intravenous and oral MDL 17043.
Cardiac index, stroke volume index and stroke work index
increased significantly after both intravenous and oral
administration, and remained elevated during the 4 hours
of observation. There was a marked decrease in right atrial
pressure, pulmonary capillary wedge pressure and systemic
vascular resistance after both intravenous and oral therapy,
and these changes were persistent for a least 4 hours.
The average percent change from control to peak hemo-
dynamic effects after intravenous and oral MDL 17043 in
all patients is illustrated in Figure 1. The average increase
in stroke volume index and stroke work index was 59 and
68%, respectively, after intravenous administration, and 53
and 58%, respectively, after oral administration, indicating
no significant difference between intravenous and oral ther-
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Table 1. Hemodynamic Effects of Intravenous MDL 17043 in Patients With Congestive Heart Failure
Control 12.5 min 30 min I h 2 h 3h 4 h
Heart rate (beats/min) 86 ± 14 93 ± 14 94 ± 16 92 ± 15 90 ± I 90 ± 16 90 ± 14
MAP (mm Hg) 81 ± II 73 ± 8* 73 ± 10* 74 ± 10* 75 ± lit 74 ± 9t 76 ± 9:j:
PAP (mm Hg) 38 ± 7 29 ± 8* 29 ± 8* 31 ± 9* 30 ± 8* 30 ± 9* 30 ± 10*
PCW (mm Hg) 26 ± 6 15 ± 7* 15 ± 6* 16 ± 6* 18 ± 8* 18 ± 6* 20 ± 7*
RAP (mm Hg) 14 ± 8 7 ± 6* 7 ± 6* 8 ± 6* 8 ± 6* 8 ± 6* 9 ± 6*
SVR (dynes-s-cm- 5) 1,528 ± 56 908 ± 275* 880 ± 66* 960 ± 315* 1,070 ± 430* 1,040 ± 23* 1,140 ± 427*
PVR (dynes-s-cm- 5) 275 ± 145 198 ± 10* 194 ± 107* 214 ± 116t 218 ± 134t 213 ± 05t 213 ± 115t
SVI (rnl/rrr') 25 ± 6 37 ± 11* 38 ± 10* 36 ± 8* 34 ± 9* 34 ± 9* 32 ± 9*
CI (liters/min per rrr') 2 ± 0.4 3.4 ± 0.9* 3.5 ± 0.9* 3.2 ± 0.7* 3 ± 0.7* 3 ± 0.6* 2.8 ± 0.7*
SWI (g-m/m'') 19 ± 7 30 ± 10* 30 ± 10* 29 ± 10* 26 ± 10* 26 ± 10* 25 ± 10*
*p < 0.001 vs. control; tp < 0.01 vs. control; :l:p < 0.05 vs. control. CI = cardiac index; MAP = mean arterial pressure; PAP = mean pulmonary
arterial pressure; PCW = mean pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; RAP = mean right atrial pressure; SVI
= stroke volume index; SVR = systemic vascular resistance; SWI = stroke work index.
apy. The average decrease in right atrial pressure, pulmo-
nary capillary wedge pressure and systemic vascular re-
sistance was similar after intravenous and oral therapy.
Clinical follow-up (Fig. 2). Thirty-seven patients were
discharged from the hospital receiving long-term oral ther-
apy with MDL 17043 (mean dosage 6.8 mg/kg three times
daily; range 2 to 10 mg/kg). Adverse side effects believed
to be attributable to MDL 17043 therapy (Table 3) resulted
in discontinuation of therapy in 11 patients (30%). Seven
of these 11 patients discontinued treatment on their own,
outside of the hospital, and the remaining 4 patients had
MDL 17043 discontinued in the hospital by a physician.
Six of seven patients discontinuing their own medication
died within approximately 1 week of doing so, five because
of severe congestive heart failure and two suddenly. MDL
17043 was discontinued for reasons other than adverse side
effects in two patients (Fig. 2). Marked sustained improve-
ment in clinical status prompted the referring physician to
discontinue treatment in one patient, and spontaneous de-
terioration in clinical status after 4 months of treatment
prompted the use of other investigational agents in another
patient.
Of 37 patients discharged from the hospital while re-
ceiving oral MDL 17043 therapy, 33 had acute clinical
improvement by at least one functional class. The functional
class at baseline (control) and early (:s 2 weeks) and late
(mean 5.6 months) follow-up evaluation is shown in Figure
3. Twenty-four of 26 patients (92% tolerating long-term
MDL 17043 treatment) experienced improvement in clinical
class acutely. The clinical status of 9 of the 12 patients who
died during the follow-up period either did not improve
acutely or deteriorated after a transient period of clinical
improvement.
The overall mortality rate in the 37 patients discharged
from the hospital on oral MDL 17043 therapy was 55% at
a mean follow-up period of 5.6 months (range 0.5 to 13).
Baseline hemodynamic measurements and their changes after
MDL 17043 therapy as well as the underlying cause of
congestive heart failure were not predictive of subsequent
survival. Functional class at entry influenced survival (Fig.
4). Mortality during follow-up while receiving MDL 17043
therapy was 18% for patients in functional class III and 62%
for 26 patients in class IV (p<0.05).
Discussion
Hemodynamic effects. This study provides confirma-
tory evidence that intravenous MDL 17043 produces marked
Table 2. Hemodynamic Effects of Oral MDL 17043 in Patients With Congestive Heart Failure
Control 12.5 min 30 min I h 2 h 3 h 4h
Heart rate (beats/min) 91 ± 26 90 ± 15 91 ± 15 91 ± 14 93 ± 14 93 ± 14 92 ± 16
MAP (mm Hg) 79 ± II 78 ± 13 74 ± 10:1: 74 ± 9:1: 71 ± 9* 72 ± 10* 74 ± 1):j:
PAP (mm Hg) 38 ± 9 32 ± 8* 32 ± 8* 30 ± 8* 30 ± 8* 30 ± 9* 31 ± 10*
PCW (mm Hg) 26 ± 7 19 ± 7* ts ± 8* 18 ± 9* 17 ± 8* 18 ± 8* 18 ± 9*
RAP (rnm Hg) 13 ± 8 9 ± 6* 8 ± 7* 8 ± 7* 8 ± 6* 8 ± 6* 8 ± 7*
SVR (dynes-s-cmr ') 1,405 ± 430 1,061 ± 331* 997 ± 336* 996 ± 351* 930 ± 92* 915 ± 260* 1,023 ± 260*
PVR (dynes-s-cm- 5) 262 ± 152 206 ± 98t 208 ± 120+ 191 ± 135* 200 ± 132t 183 ± 34* 209 ± 35:1:
SVI (ml/rrr') 25 ± 7 34 ± 9* 35 ± 8* 34 ± 8* 35 ± 7* 35 ± 8* 33 ± 8*
CI (liters/min per rrr') 2.2 ± 0.5 3 ± 0.6* 3.1 ± 0.7* 3.1 ± 0.7* 3.2 ± 0.6* 3.2 ± 0.6* 3 ± 0.6*
SWI (g-m/m-) 19 ± 9 28 ± 11* 27 ± 10* 27 ± 11* 26 ± 9* 26 ± 10* 26 ± 11*
*p < 0.001 vs. control; tp < 0.01 vs. control; :l:p < 0.05 vs. control. Abbreviations as in Table I.
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Figure 1. Comparative magnitude of the effect of in-
travenous and oral MOL 17043 in 38 patients with
congestive heart failure. Thepercent change from base-
line at peak drugeffect of each hemodynamic variable
is similar after either route of administration. Cl =
cardiac index; HR = heart rate; MAP = mean arterial
pressure; MPA = mean pulmonary arterial pressure;
PCW = mean pulmonary capillary wedge pressure;
PYR = pulmonary vascular resistance; RAP = mean
right atrial pressure; SYI = stroke volume index; SYR
= systemic vascular resistance;SWI = leftventricular
stroke work index.
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hemodynamic improvement in patients with severe conges-
tive heart failure (8). There was a marked increase in cardiac
output along with a substantial decrease in pulmonary and
systemic venous pressures (the two major hemodynamic
objectives for the therapy of heart failure). Hemodynamic
effects were sustained during the 4 hours of observation.
This study also demonstrates that oral MOL 17043produces
marked improvement in left ventricular function in patients
with chronic refractory heart failure. Hence, it is potentially
a useful pharmacologic agent for the long-term management
of patients with heart failure.
Mechanisms of drug action. Although this study dem-
onstrates that both intravenous and oral MOL 17043 cause
marked improvement in left ventricular pump function in
patients with severe heart failure, it does not elucidate the
potential mechanisms for its beneficial response. In vitro
experimental studies (6) suggest that MOL 17043 exerts
positive inotropic effects and causes arterial vasodilation
(6). A significant increase in the first derivative of left ven-
tricular pressure (dP/dt) has been demonstrated in conscious
dogs (11) given MOL 17043 orally and in human patients
(7) after intravenous administration. Increased left ventric-
ular dP/dt occurred in the absence of increased heart rate
or arterial pressure, and even when left ventricular filling
pressure decreased markedly. These hemodynamic changes
suggest enhanced contractile function. In the present study,
we did not evaluate changes in contractile function after
MOL 17043therapy. Thus, it is uncertain whether enhanced
contractile function was contributory in improving left ven-
tricular function in our patients.
A direct arterial vasodilator effect of MOL 17043 has
been demonstrated (6) in the isolated, perfused dog hind
limb. Whether MOL 17043causes any change in venomotor
tone remains to be investigated. In this study, systemic
vascular resistance decreased markedly after both intrave-
nous and oral MOL 17043. Decreased systemic vascular
resistance must have been associated with reduced left ven-
tricular ejection impedance and contributory to improved
left ventricular function.
Clinical status. Our data suggest that symptomatic im-
provement occurs in the vast majority of patients even with
severe functional class IV heart failure after MDL 17043.
In this study, 33 of 37 patients experienced clinical im-
provement initially and 16 patients had sustained clinical
improvement. The clinical status of some patients, however,
deteriorated after initial improvement and the majority of
Figure 2. Clinical course of 37 patients dis-
charged from the hospital while receiving oral
MOL 17043 therapy. Therapy was discon-
tinued in II patients because of adverse side
effects andin 2 patients (*) forother reasons
(see text) . Sixofseven patients discontinuing
MDL 17043 ontheir own (out ofthehospital)
died. CHF = congestive heart failure ; SCD
= sudden cardiac death.
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Table 3. Adverse Side Effects During MOL 17043 Therapy in
37 Patients
Numbers in parentheses represent the number of patients who expe-
rienced the particular side effect.
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% PatientsSigns and Symptoms
Nausea
Anorexia
Fluid retention
Vomiting
Diarrhea
Fluctuating liver function tests
Thrombocytopenia
Rash
Abdominal bloating
Altered taste sensation
these patients died. The mechanism for deterioration in heart
failure after initial improvement remains unclear. Enhanced
myocardial ischemia due to increased myocardial oxygen
Figure 3. New York Heart Association (NYHA) functional class
at control, early (:52 weeks) and late (mean 5.6 months) follow-
up in 37 patients with congestive heart failure receiving oralMOL
17043. Eleven patients discontinued MOL 17043 because of ad-
verse effects during long-term follow-up (triangles). After dis-
continuation of therapy, seven patients died(.A) andfour remained
alive (6). Of 24 patients tolerating long-term therapy (circles),
12patients remained alive (0) and 12died (e) during follow-up.
MOL 17043 was discontinued for reasons other than adverse ef-
fects in two patients (*). t = sudden cardiac death.
NYHA
CLASS
II
III
IV
CONTROL EARLY LATE
3 6 9
MONTHS OFTREATMENT WITH MOL 170113
Figure 4. Cumulative survival as a function of New York Heart
Association (NYHA) functional class at entryto study during long-
term oral therapy withMOL 17043 in 37 patients with congestive
heart failure. Survival was significantly influenced by functional
class (p < 0.05) during a mean follow-up period of 5.6 months
(range 0.5 to 13) with mortality rate being 18 and 62% in class
III and IV patients, respectively.
consumption associated with increased contractility, atten-
uation of the hemodynamic effects and progression of the
underlying disease are all potential mechanisms. Further
studies are needed to elucidate the cause of this deterioration
of clinical status after initial improvement during mainte-
nance MDL 17043 therapy in patients with severe heart
failure.
Adverse effects. Most common among probable drug-
related adverse effects were gastrointestinal complaints of
anorexia and nausea, with vomiting and diarrhea occurring
less frequently. These gastrointestinal side effects appear to
be similar to those produced by other phosphodiesterase-
inhibiting drugs and were frequently improved after reduc-
tion of MDL 17043 dosage. Loose stools and vomiting have
been noted in toxicity studies (6) of animals given MDL
17043. Fluid retention necessitating an alteration in diuretic
drug therapy occurred in 24% of our patients. Although the
exact mechanism is unknown, fluid retention may result
from the vasodilator action of the drug, causing secondary
activation of the renin-aldosterone system. Fluid retention
was successfully managed in most cases by increasing di-
uretic drug dosage or adding an aldosterone antagonist, or
both. Thrombocytopenia occurred in two patients, 3 and 4
weeks, respectively, after the initiation of therapy and was
not associated with significant bleeding complications. Blood
plateletcounts reacheda nadirof 34,OOO/mm3 and 35,OOO/mm3
in the two patients and returned to the pretreatment levels
within 1 week of discontinuing MDL 17043 therapy. Re-
challenge with MDL 17043 was not performed in either
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patient, but the temporal relation to the development of
thrombocytopenia strongly suggests that it was MDL 17043-
induced. However, because all patients were undergoing
multiple drug therapy, direct relation of the adverse effects
attributed to MDL 17043 cannot be determined with cer-
tainty without a controlled study.
Mild elevation in serum glutamic oxaloacetic transami-
nase levels occurred in five patients during MDL 17043
treatment. In no case did the level exceed four times the
limit of normal (37 IV/liter) and total bilirubin did not ex-
ceed 3.9 mg %. These abnormalities returned toward normal
with continued treatment and most likely reflected fluctua-
tions in congestive hepatopathy related to heart failure.
Adverse clinical side effects, however, necessitated dis-
continuation of treatment in 11 patients in this study. Of
seven patients discontinuing treatment of their own accord
while outside the hospital, six died with 4 to 7 days of
discontinuation (five of severe rapidly deteriorating conges-
tive heart failure and one suddenly). Of four patients having
MDL 17043 treatment discontinued in the hospital, all were
successfully managed with other medications and remained
alive. Although we have no data to support a "rebound"
phenomenon after discontinuation of MDL 17043, our ob-
servations suggest the need for caution and close observation
when MDL 17043 treatment is discontinued.
Influence on survival. Mortality during long-term fol-
low-up was most clearly related to functional clinical class
at entry to the study (18% in patients in class III; 62% in
patients in class IV). Survival in our class III and IV patients
treated with MDL 17043 is virtually identical to that recently
reported (12, 13) for similar patients treated with more con-
ventional therapy. In the study of Califf et al. (12), in which
only 15% of the patients were treated with a specific vaso-
dilator regimen in addition to receiving digoxin and diuretic
drugs, and in the study of Wilson et al. (13), in which 51%
received vasodilator therapy, the mortality rate for class IV
patients was 50% or greater at 6 months. Both of these
studies as well as our own data show a particularly high
initial mortality rate during the first 4 months of follow-up.
This is most likely explained by the referral nature of the
patients studied and the fact that referral is often prompted
by an apparent worsening of a patient's clinical status. Those
patients with progressively worsening heart failure before
referral have a higher early mortality than those with a more
stable level of function (14). Furthermore, the majority of
patients were referred because of failure to respond not only
to conventional therapy but also to vasodilator agents, in-
dicating refractory heart failure.
Thus, the results of the present study suggest that the
survival of patients with severe congestive heart failure (class
IV) is not improved despite symptomatic improvement and
improvement in left ventricular function with MDL 17043.
Lack of predictive value of the hemodynamic abnormalities
at rest for long-term survival as observed in the present
study has been reported by Wilson et al. (13). Furthermore,
the magnitude of improvement in left ventricular function
after MDL 17043 could not be related to survival. These
results are at variance with our previous observations (14),
which demonstrated a correlation between the severity of
left ventricular failure at rest and the magnitude of hemo-
dynamic improvement after vasodilator therapy and late sur-
vival. The cause of this discrepancy is not obvious, but the
differences in the groups of patients, the relatively small
number of patients being studied and the different thera-
peutic interventions may have been contributory.
Conclusions. Both intravenous and oral administration
of MDL 17043 are associated with marked improvement in
left ventricular function in patients with severe congestive
heart failure. However, adverse side effects, particularly
gastrointestinal complaints, can occur in many patients. Most
patients receiving MDL 17043 improve clinically, but long-
term survival does not appear to be improved.
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